RhumbLine Advisers
SMTI icon

RhumbLine Advisers’s Sanara MedTech SMTI Stock Holding History

RhumbLine Advisers’s Portfolio SMTI Stock Details SMTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.1K Buy
2,550
+380
+18% +$7.86K ﹤0.01% 3649
2026
Q1 		$37.3K Sell
2,170
-38
-2% -$782 ﹤0.01% 3641
2025
Q4 		$51.6K Sell
2,208
-919
-29% -$23.7K ﹤0.01% 3634
2025
Q3 		$99.2K Sell
3,127
-362
-10% -$10.9K ﹤0.01% 3521
2025
Q2 		$99K Sell
3,489
-225
-6% -$6.75K ﹤0.01% 3529
2025
Q1 		$115K Buy
3,714
+483
+15% +$16.4K ﹤0.01% 3343
2024
Q4 		$107K Buy
3,231
+112
+4% +$3.8K ﹤0.01% 3459
2024
Q3 		$94.3K Sell
3,119
-226
-7% -$7.05K ﹤0.01% 3511
2024
Q2 		$94.4K Buy
3,345
+43
+1% +$1.35K ﹤0.01% 3528
2024
Q1 		$122K Buy
3,302
+281
+9% +$10.5K ﹤0.01% 3379
2023
Q4 		$124K Sell
3,021
-105
-3% -$3.37K ﹤0.01% 3377
2023
Q3 		$97.3K Buy
3,126
+209
+7% +$8.1K ﹤0.01% 3472
2023
Q2 		$117K Buy
+2,917
New +$119K ﹤0.01% 3459

Other funds holding SMTI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
SWM
Stonebridge Wealth Management Oak Brook, Illinois $112M AUM 23.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

RhumbLine Advisers's SMTI Position: Q2 2026 in Review

RhumbLine Advisers increased its Sanara MedTech (SMTI) stake by 18% in Q2 2026, buying an estimated $7.86K and bringing the position to 2,550 shares worth $60.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3649.

RhumbLine Advisers first reported a position in SMTI in Q2 2023 and has held it in 13 quarters since. The position peaked at $124K in Q4 2023. 75 funds tracked by Wall St. Rank hold SMTI as of Q2 2026.

  • RhumbLine Advisers held 2,550 shares of Sanara MedTech worth $60.1K as of Q2 2026.
  • RhumbLine Advisers bought 380 Sanara MedTech shares in Q2 2026, an estimated $7.86K.
  • Sanara MedTech made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3649 holding.
  • RhumbLine Advisers first reported a position in Sanara MedTech in Q2 2023 and has held it in 13 quarters since.
  • RhumbLine Advisers's Sanara MedTech position peaked at $124K in Q4 2023.
  • 75 funds tracked by Wall St. Rank held Sanara MedTech as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.